Roche Holding | ROG - Current Liabilities


Roche Holding reported CHF28.85B in Current Liabilities for its fiscal semester ending in June of 2026.





Current Liabilities Change Date
AbbVie USD 43.1B 1.46B Sep/2026
Alcon AG USD 3.17B 163M Jun/2026
Almirall EUR 323.65M 26.99M Jun/2026
Amgen USD 23.23B 2.27B Sep/2026
AstraZeneca USD 31.27B 286M Sep/2026
Bayer EUR 29.4B 2.87B Sep/2026
Biogen USD 3.9B 18.7M Sep/2026
Bristol-Myers Squibb USD 18.75B 94M Sep/2026
Eli Lilly USD 47B 745M Sep/2026
Fresenius EUR 8.08B 986M Sep/2026
Fresenius Medical Care EUR 7.91B 727.93M Sep/2026
Genmab DKK 1.14B 38M Jun/2026
Gilead Sciences USD 12B 982M Sep/2026
GlaxoSmithKline GBP 20.72B 814M Sep/2026
GRIFOLS EUR 2.3B 59M Sep/2026
Hikma Pharmaceutical USD 1.45B 603M Dec/2025
Lakefront Biotherapeutics EUR 70.32M 30.1M Jun/2026
Lonza CHF 3.57B 421M Dec/2025
Merck EUR 8.96B 833M Sep/2026
Merck USD 28.8B 1.07B Sep/2026
Novartis USD 32.52B 777M Sep/2026
Orion EUR 491.8M 37.3M Sep/2026
Pfizer USD 31.73B 920M Sep/2026
Philips EUR 7.91B 485M Sep/2026
Recordati EUR 1.4B 4.3M Sep/2026
Regeneron Pharmaceuticals USD 6.2B 671.5M Sep/2026
Roche Holding CHF 28.85B 846M Jun/2026
Sanofi EUR 29.77B 2.16B Sep/2026
UCB EUR 4.4B 470M Dec/2025